一个新型PCSK9反意义寡核酸的模型信息化药物开发的案例研究. 第二部分:第二阶段到第三阶段
Jane Knöchel1, Catarina Nilsson1, Björn Carlsson2
1Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca AB R&D, Gothenburg, Sweden.
基于模型的药物开发 (MIDD) 指导了AZD8233的临床进展,这是一个新的PCSK9反感性寡核酸. 模拟优化了第三阶段试验,预测显著的LDL-C降低和心血管风险降低.
科学领域:
- 制药指标 (Pharmacometrics) 是一个指标.
- 临床药理学 临床药理学
- 药物开发 药物开发
背景情况:
- 基于模型的药物开发 (MIDD) 对于优化临床试验设计和决策至关重要.
- 本案例研究详细介绍了MIDD在AZD8233的开发中的应用,AZD8233是一种新型的proprotein转化酶亚素/kexin类型9 (PCSK9) 反感性寡核酸.
更多相关视频
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
相关概念视频
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
